Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
140.50    3.25 (2.36%)
Bid:
138.00
Ask:
144.50
Spread: 6.50 (4.71%)
Market Cap: £110.25m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Systems integration partner

13 May 2005 07:01

Xaar PLC13 May 2005 FOR IMMEDIATE RELEASE 13 May 2005 Xaar plc IMPIKA APPOINTED AS SYSTEMS INTEGRATION PARTNER Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, and IMPIKA SA ("IMPIKA") of Aubagne, France are pleased to announce ajoint agreement for the provision of integration services for Xaar printheadsand other products. Under the agreement both parties will co-operate to provide complete turnkeysolutions for clients wishing to use Xaar technology for their productionprocesses, to open up new applications and create bespoke solutions. IMPIKA haslong experience with inkjet, including its application to the printing ofplastic and smart cards, packaging, labelling as well as special applicationsfor printing on CDs, glass and metal. Impika is also developing solutions basedon its material jetting technology for microelectronics and biomedicalapplications. Nigel Berry, Deputy CEO of Xaar commented: "I am very pleased to announce thisrelationship with IMPIKA. We previously stated our intention to partner with asmall number of high quality integrators which can offer existing and potentialusers of our technology a complete package of integration skills and bespokeequipment. We have known the team at IMPIKA for some time now and have beenimpressed by their standards and innovation. I look forward to working withthem on future projects." Paul Morgavi, IMPIKA'S CEO said: "Xaar is a great partner for us and we arealready forming strong links with their technical and marketing teams. There isa clear synergy between Xaar and Impika with both parties introducing newmarkets into the joint relationship. Last year we introduced our C9000 productbased on Xaar's Leopard printhead and we are working on various projects foradapting our IPS print engine to the next generation of Xaar printheads, likethe Omnidot and HSS. Full commercial release of these products is anticipatedlater this year or early next year." About Xaar Xaar plc is a market-leading inkjet technology company. It targets the world'sindustrial, commercial and office printing markets. The industrial andcommercial printing markets are targeted by Xaar's own range of inkjet productsin conjunction with partners and other key players in those markets; the officeprinting market is approached through Xaar's strong list of licensees.Additional information about Xaar is available at www.xaar.co.uk. About IMPIKA: Created in March 2003 as a spin-out from Gemplus, IMPIKA is headquartered atAubagne in the south of France. IMPIKA offers high-performance industrialprinting and material jetting solutions using inkjet technology; it currentlyhas 37 employees. IMPIKA designs, develops, implements and markets hardware and softwaresolutions, as well as the required engineering as regards ink and materialjetting, for industrial applications including digital printing,microelectronics and biotechnologies. Additional information about IMPIKA isavailable at www.impika.com. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive IMPIKA: +33 (0)4 42 62 43 00Paul Morgavi, CEO www.impika.com Bankside Consultants:Steve Liebmann 020-7444-4163 /07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Sep 20239:57 amRNSHolding(s) in Company
19th Sep 20237:00 amRNS2023 Interim Results
11th Sep 20232:11 pmRNSHolding(s) in Company
11th Sep 202312:14 pmRNSHolding(s) in Company
11th Sep 202312:07 pmRNSHolding(s) in Company
11th Sep 202312:03 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
7th Sep 20239:00 amRNSNotice of 2023 Half Year Results
1st Sep 20239:30 amRNSTotal Voting Rights
25th Aug 202312:13 pmRNSHolding(s) in Company
23rd Aug 202310:24 amRNSHolding(s) in Company
18th Aug 202310:30 amRNSChange of Auditor
17th Aug 202312:55 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSTrading Update
1st Aug 20232:00 pmRNSTotal Voting Rights
28th Jul 20234:30 pmRNSHolding(s) in Company
5th Jul 20239:00 amRNSXaar plc - Commercial partnership with Quantica
4th Jul 20233:00 pmRNSBlock listing Interim Review
3rd Jul 20232:53 pmRNSTotal Voting Rights
1st Jun 202310:37 amRNSTotal Voting Rights
31st May 202311:30 amRNSResult of AGM
31st May 20239:00 amRNSBoard Changes
11th May 20235:41 pmRNSHolding(s) in Company
10th May 20233:10 pmRNSDirector/PDMR Shareholding
2nd May 202312:39 pmRNSTotal Voting Rights
24th Apr 20231:05 pmRNSAnnual Financial Report
3rd Apr 20234:51 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSFinal Results
20th Mar 20232:00 pmRNSNotification of the 2022 Full Year Results Date
1st Mar 20233:19 pmRNSTotal Voting Rights
20th Feb 202312:35 pmRNSHolding(s) in Company
1st Feb 202312:30 pmRNSTotal Voting Rights
30th Jan 202312:30 pmRNSHolding(s) in Company
12th Jan 20237:00 amRNSTrading Update
5th Dec 202210:21 amRNSDirector/PDMR Shareholding
1st Dec 202210:19 amRNSTotal Voting Rights
21st Nov 20224:41 pmRNSSecond Price Monitoring Extn
21st Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20221:38 pmRNSGrant of Sharesave Options
1st Nov 202210:41 amRNSTotal Voting Rights
13th Oct 20222:20 pmRNSHolding(s) in Company
3rd Oct 20224:07 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNS2022 INTERIM RESULTS
1st Sep 20225:32 pmRNSTotal Voting Rights
30th Aug 202210:26 amRNSNotice of 2022 Half Year Results
1st Aug 20224:33 pmRNSTotal Voting Rights
1st Aug 202211:25 amRNSHolding(s) in Company
14th Jul 20227:00 amRNSTrading Update
1st Jul 20221:14 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.